FFECT OF LIRAGLUTIDE ON CARDIOVASCULAR RISK FACTORS AND FUNCTION
Journal Title: Romanian Journal of Diabetes Nutrition and Metabolic Diseases - Year 2011, Vol 18, Issue 3
Abstract
Cardiovascular disease is the major cause of death in diabetes. This results from a cluster of risk factors, including high glucose, obesity, hypertension and dyslipidaemia. Liraglutide is the first native GLP-1 analogue and represents a breakthrough approach in type 2 diabetes treatment. Previous data from the LEAD™ programme have shown liraglutide to be a potent glucose regulator, but also to induce weight loss, lower blood pressure, and potentially show improvements in lipid levels, amongst other markers of cardiovascular risk. GLP-1 has also been shown to have an effect on the renal system, as well as the vascular system. Other cardio-protective effects of GLP-1 were proved in animal models: improves cardiac function in heart failure, functional recovery following myocardial ischemia, endothelium dysfunction, increases myocardial glucose uptake and reduces infarct size. Cardiovascular safety of liraglutide was assessed using existing clinical data. The incidence ratio for adjudicated broad/serious major adverse cardiovascular events (MACE) associated with liraglutide was 0.73 (95% CI 0.38–1.41) versus all comparator drugs, within cardiovascular safety limits defined by the United States Food & Drug Administration.
Authors and Affiliations
Maria Mota, Emiliana Mocan, Sorina Botescu
Keywords
Related Articles
- EP ID EP113933
- DOI -
- Views 100
- Downloads 0
CHANGES IN PHYSICAL PROPERTIES OF SKIN IN PATIENTS WITH INSUFFICIENT THERAPEUTIC CONTROLLED DIABETES MELLITUS
Cutaneous complications are common in diabetes. Previous assays suggest that hyperglycemia and decreased insulin signal/secretion are involved in the impairment of skin function. Objective: To evaluate the biophysical ch...
Educational Play For Pre-School Children Suffering From Type 1 Diabetes Mellitus
Education is the keystone of diabetes care and management. The Diabetes Control and Complications Trial (DCCT) provided clear evidence that successful intensification of management reduces microvascular complications. Bu...
METABOLIC SYNDROME IN PATIENTS WITH T1DM OLDER THAN 10 YEARS
Metabolic Syndrome (MS) is a clinical entity recently individualized, a clinical concept with multiple definitions that expresses a complex disorder of the body′s energy metabolism, with insulin resistance and compensato...
DIABETES MELLITUS EPIDEMIOLOGY
The worldwide diabetes epidemics is evolving proportionally with the overweight/obesity epidemics. 246 million people with diabetes (type 2 diabetes constituting about 90%) were registered worldwide in 2007. It was estim...